BSX

Boston Scientific (BSX) closed at $44.14, up 2.65% on the day but down 2.07% over the past month. The company is expected to report earnings on October 28, 2026, with projected EPS of $0.76 and revenue of $5.17 billion. Despite trading at a Forward P/E discount of 13.28 compared to its industry average of 19.61, BSX carries a Zacks Rank #4 (Sell) rating due to a 1.49% downward revision in consensus EPS projections over the past 30 days.

Boston Scientific (BSX) closed at $42.73, up 1.64% on the day, outperforming the S&P 500. The company is expected to report earnings on October 28, 2026, with predicted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY).

However, BSX holds a Zacks Rank #4 (Sell) rating due to a 1.3% decline in consensus EPS estimates over the past month. The stock trades at a Forward P/E of 12.92, below its industry average, but faces headwinds despite valuation appeal.

Boston Scientific (BSX) gained 1.11% on October 8, 2026, outperforming the broader market decline. The medical device manufacturer is expected to report Q3 earnings on October 28 with forecasted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY).

However, the stock has declined 7.52% over the past month and holds a Zacks Rank of #4 (Sell) following a 1.3% decrease in consensus EPS estimates over the last 30 days. The stock trades at a Forward P/E of 12.78, below its industry average of 19.24.